A new study from Stanford Medicine has thrown a spotlight on a potential breakthrough in slowing the progression of Parkinson’s disease, leaving researchers pleasantly surprised. Published in the journal Science Signaling, the research dives into the role of enzymes, which are essential proteins for various bodily functions, in the development of Parkinson’s. The Stanford team discovered that by targeting a specific enzyme, they could restore communication between neurons and cells in mice.
Suzanne Pfeffer, PhD, who led the study, shared with Fox News Digital that the extent of improvement observed was unexpected. In approximately 25% of Parkinson’s cases, the condition is driven by a genetic mutation, one of which leads to an overactive enzyme known as LRRK2. This overactivity disrupts brain cell structures, affecting crucial communication needed for movement and decision-making.
The researchers aimed to find out if a molecule called MLi-2 LRRK2 kinase inhibitor could counteract the effects of these hyperactive enzymes. They experimented with mice carrying the genetic mutation associated with overactive LRRK2, mirroring early Parkinson’s symptoms. Initially, after two weeks of administering the inhibitor, there were no noticeable changes in brain structure or dopamine neuron function.
Yet, after three months, the mice showed significant neuron restoration, aligning closely with those without the genetic mutation. Pfeffer noted in a press release, “Findings from this study suggest that inhibiting the LRRK2 enzyme could stabilize the progression of symptoms if patients can be identified early enough.” This discovery points to the potential for early intervention in slowing the disease’s progression.
The study wasn’t without its limitations, as it was conducted on mice and not humans. Pfeffer explained to Fox News Digital that despite this, the pathways seem crucial in humans too. Even though the research targeted a specific genetic variant, overactive LRRK2 also appears in other Parkinson’s cases, suggesting broader potential applications for this treatment.
The team is eager to explore the implications of their findings on other Parkinson’s variants. With Parkinson’s affecting nearly a million Americans, early intervention is vital, as symptoms often manifest years after onset. “These findings suggest that it might be possible to improve, not just stabilize, the condition of patients with Parkinson’s disease,” Pfeffer mentioned.
Encouraging genetic testing for patients could pave the way for more personalized treatment approaches. The study received funding from notable organizations like The Michael J. Fox Foundation for Parkinson’s Research. Khloe Quill, a lifestyle production assistant at Fox News Digital, highlights various topics, including health insights like these, to keep the public informed.
Add comment